Seeking Alpha·6d ago
COMPASS Pathways plc (CMPS) Presents at Deutsche Bank 2026 Healthcare Summit TranscriptCOMPASS Pathways plc (CMPS) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
COMPASS Pathways remains a pre-revenue clinical-stage biotech with escalating R&D and SG&A costs, driving quarterly operating losses from $38.6M in 2024Q1 to $52.4M in 2026Q2. The company's cash runway is pressured by a 324% increase in free cash flow burn ove...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.36+21.7% vs -$0.46 | — vs — |
Q2 2026 May 13, 2026 | -$0.30+33.3% vs -$0.45 | — vs — |
Q2 2026 Mar 24, 2026 | -$1.00-143.9% vs -$0.41 | — vs — |
Q4 2025 Nov 4, 2025 | -$1.44-260.0% vs -$0.40 | — vs — |
COMPASS Pathways plc (CMPS) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
COMPASS Pathways plc (CMPS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and will participate in a fireside chat at 1:00pm ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/fAK4ioHxQNLX5.
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the T.
Benchmark CMPS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for COMPASS Pathways plc (CMPS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.75 | $1.86B | -4.46 | — | — | -565.28% | — | |
| $42.79 | $3.23B | -20.77 | — | — | -102.48% | — | |
| $7.35 | $2.72B | -2.53 | 1227.6% | -14938.37% | -353.02% | — | |
| $6.09 | $303.86M | -13.66 | — | — | -81% | — | |
| $0.94 | $45.26M | -1.80 | — | — | -95.77% | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — |
COMPASS Pathways plc (CMPS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
COMPASS Pathways plc (CMPS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 7, 2026·SEC
May 28, 2026·SEC
Get notified when CMPS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
COMPASS Pathways plc (CMPS) stock FAQ — growth, dividends, profitability & financials explained
COMPASS Pathways plc (CMPS) reported a net loss of $394.2M for fiscal year 2025.
COMPASS Pathways plc (CMPS) has a return on equity (ROE) of -565.3%. Negative ROE indicates the company is unprofitable.
COMPASS Pathways plc (CMPS) had negative free cash flow of $209.1M in fiscal year 2025, likely due to heavy capital investments.
